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Abstract
Background: Recent data provide significant evidence to support the hypothesis that there are sub-populations of
cells within solid tumors that have an increased tumor initiating potential relative to the total tumor population.
CD133, a cell surface marker expressed on primitive cells of neural, hematopoietic, endothelial and epithelial
lineages has been identified as a marker for tumor initiating cells in solid tumors of the brain, colon, pancreas,
ovary and endometrium. Our objectives were to assess the relative level of CD133 expressing cells in primary
human endometrial tumors, confirm their tumorigenic potential, and determine whether CD133 expression was
epigenetically modified.
Methods: We assessed CD133 expression in primary human endometrial tumors by flow cytometry and analyzed
the relative tumorigenicity of CD133+ and CD133- cells in an in vivo NOD/SCID mouse model. We assessed
potential changes in CD133 expression over the course of serial transplantation by immunofluorescence and flow
cytometry. We further examined CD133 promoter methylation and expression in normal endometrium and
malignant tumors.
Results: As determined by flow cytometric analysis, the percentage of CD133+ cells in primary human endometrial
cancer samples ranged from 5.7% to 27.4%. In addition, we confirmed the tumor initiating potential of CD133+
and CD133
- cell fractions in NOD/SCID mice. Interestingly, the percentage of CD133+ cells in human endometrial
tumor xenografts, as evidenced by immunofluorescence, increased with serial transplantation although this trend
was not consistently detected by flow cytometry. We also determined that the relative levels of CD133 increased in
endometrial cancer cell lines following treatment with 5-aza-2’-deoxycytidine suggesting a role for methylation in
the regulation of CD133. To support this finding, we demonstrated that regions of the CD133 promoter were
hypomethylated in malignant endometrial tissue relative to benign control endometrial tissue. Lastly, we
determined that methylation of the CD133 promoter decreases over serial transplantation of an endometrial tumor
xenograft.
Conclusions: These findings support the hypotheses that CD133 expression in endometrial cancer may be
epigenetically regulated and that cell fractions enriched for CD133+ cells may well contribute to endometrial
cancer tumorigenicity, pathology and recurrence.
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Endometrial cancer is the most common cancer of the
female reproductive organs in the United States [1-5].
The continual remodeling of the endometrial lining at
menses strongly argues for the presence of a stem/pro-
genitor cell population with regenerative capabilities.
This is further supported by studies of the benign endo-
metrium in primate models and clonogenicity assays of
human derived uterine cells [6-10]. Mouse studies utiliz-
ing pulse-chase experiments to demonstrate evidence of
label retaining cells in the uterus [11,12] provide addi-
tional functional evidence to support this concept. Thus,
i th a sb e e np r o p o s e dt h a ta na b e r r a n ts t e m / p r o g e n i t o r
cell or a cell that regains some stem-like properties can
contribute to pre-malignant endometrial hyperplasia
and/or endometrial cancer [6,7,13].
Several investigators have identified putative stem/pro-
genitor cells in solid tumors and cancer cell lines within
the side population (SP), which is distinguished by dif-
ferential efflux of Hoechst 33342 dye via verapamil-
sensitive multidrug resistance transporters [14-16]. Our
previous work [13] identified a tumorigenic SP within a
human endometrial cancer cell line that displayed
increased chemoresistance and quiescence in vitro rela-
tive to its non-SP counterpart. Hubbard and colleagues
[7] demonstrated endometrial cancer cells with clono-
genic, self-renewing, differentiating and tumorigenic
properties further supporting the hypothesis that a can-
cer stem cell population may be responsible for seeding
tumors or metastatic lesions.
Tumor initiating cells have been identified in leukemia
[17] and in a variety of solid tumors [18-23] based on
differential expression of one or more cell surface mar-
kers, suggesting that tumor initiating cell heterogeneity
exists for each specific tumor type. The CD133 (human
Prominin-1, AC133) cell surface antigen was originally
identified in hematopoetic stem cells [24,25] and shown
to be expressed on primitive cells of neural, endothelial
and epithelial lineages. Several investigators have identi-
fied CD133 as a potential tumor initiating cell marker in
solid tumors of the brain [18], prostate [19], colon [20]
and more recently the ovary [21,22] and endometrium
[23]. CD133
+ cells have been associated with an increase
in in vivo tumor initiation [18,26], asymmetric cell divi-
sion and increased resistance to chemotherapeutic drugs
[26], as compared to CD133
- cells. Additionally, SP frac-
tions have been reported to be enriched for CD133
+
cells [27]. In the ovary, CD133
+ cells have been asso-
ciated with the presence of primary disease rather than
with normal ovaries or metastatic omental lesions [22]
and sorted ovarian CD133
+ tumors cells form more
aggressive tumor xenografts compared to their CD133
-
progeny [26]. Similarly, CD133
+ cells isolated from
endometrioid adenocarcinomas were resistant to
cisplatin- and paclitaxel-induced cytotoxicity [23]. When
serially transplanted into NOD/SCID mice, CD133
+
cells were capable of initiating tumor formation that
resembled the phenotype of the original tumor [23].
Together these data support the hypothesis that CD133
is expressed by human endometrial cancers and may
serve as a marker of more tumorigenic cells.
Recent studies have indicated that CD133 expression
and antigenic potential [28] may be regulated in part by
histone modification [26], DNA methylation [29,30]
and/or glycosylation [28,31]. Regulation of CD133
expression by DNA methylation-dependent mechanisms
has been observed in glioblastoma [24,32], colorectal
cancer [29,30] and ovarian cancer [26]. Our objectives
were to confirm the tumorigenic potential of CD133
+
cells in immunocompromised mice, assess whether
CD133 levels increased in serially transplanted tumors
concurrently with their accelerated tumor formation
rate and determine whether methylation status was
associated with changes in the levels of CD133.
Our results confirm that endometrial tumors contain
CD133
+ cells, which can generate new tumors following
injection in NOD/SCID mice. Cell fractions enriched for
CD133
+ c e l l sg a v er i s et ot u m o r sa taf a s t e rr a t et h a n
CD133
- cell populations at fewer cell numbers injected.
Interestingly, the level of CD133
+ cells, as determined
by immunofluorescence, in tumor explants appeared to
be enriched with sequential serial transplantation of the
tumor cells although this apparent increase in CD133
levels was not consistently detected by flow cytometry.
Despite the fact that the percentage of CD133
+ cells
varies widely in established endometrial cancer cell
lines, the level of mRNA encoding CD133 was elevated
following treatment with the demethylating agent,
5-aza-2’-deoxycitidine (5-aza-dc), suggesting that methy-
lation status may be important in the regulation of
CD133 expression or epitope presentation. This concept
was further supported by evidence that the CD133 pro-
moter is hypomethylated in primary endometrial cancer
tissue compared to benign endometrium. Collectively,
these data support the hypothesis that CD133 may serve
as a marker to assess potential tumorigenicity of endo-
metrial cancer cells and that its expression levels are
controlled in part through epigenetic regulation.
Methods
Human primary endometrial epithelial cell isolation
All primary human uterine tissues were collected in
accordance with the policies of the Massachusetts Gen-
eral Hospital (MGH) Institutional Review Board. A sub-
set of samples was collected utilizing the MGH GYN
tissue repository after obtaining informed consent and a
second subset was collected as anonymized discarded
tissue. As per IRB protocol, the samples (n = 12) were
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type and grade of each sample was retrospectively assessed
by an MGH pathologist (LRZ). The details of the tumor
samples used in this study are listed in Table 1.
Endometrial carcinoma tissues were minced to yield 2
mm
3 pieces and incubated with agitation in HBSS (Cam-
brex Corp., East Rutherford, NJ)/2% FBS (HyClone,
Logan, UT)/1 mM EDTA (Sigma-Aldrich, St. Louis, MO)
containing 1 mg/ml collagenase Type II (Sigma) and
0.025% DNase I (Sigma) at 37°C for 1 hour. Following
this incubation, the supernatant was removed and dis-
carded. The remaining digested tissue was washed with
Dulbecco’s phosphate buffered saline (PBS) (Cambrex)
and resuspended in DMEM medium (Mediatech Inc.,
Herndon, VA) containing 2% FBS, added L-glutamine
(100 U/ml), penicillin (1%), streptomycin (1%) and
2.5 μg/ml amphotericin B (Sigma), and incubated in a
T75 flask at 37°C, 5% CO2 in a humidified chamber for
1 hour. The flask was rotated at 20-minute intervals dur-
ing this incubation period to maximize binding of stro-
mal cells to the vessel walls. Endometrial epithelial cells,
which make up the bulk of the cells in the non-adherent
cell population, were then removed from the flask. The
number of non-viable cells, as determined by Trypan
blue staining (Mediatech Inc.), was assessed and these
cells were eliminated from the suspension using the
Dead Cell Removal Kit (Miltenyi Biotec Inc., Auburn,
CA) as necessary.
In vivo endometrial tumorigenesis assay
All experiments utilizing mouse models were reviewed
and approved by the MGH Institutional Animal Care
and Use Committee and were performed in strict accor-
dance with the NIH Guide for the Care and Use of
Laboratory Animals. Six to twelve week old female
NOD/SCID mice (strain NOD.CB17-Prkdcscid/J,
Jackson Laboratory, Bar Harbor, ME) were used for all
injections of human primary endometrial tumor epithelial
cells. Defined numbers of isolated primary endometrial
epithelial cells were suspended in 1:1 PBS/Matrigel® (BD
Biosciences, San Jose, CA) and subcutaneously (s.c.)
injected into the right dorsal side of NOD/SCID mice.
Control animals were simultaneously injected with 1:1
PBS/Matrigel® only. Tumor development was assessed bi-
weekly.
Tumor initiating capacity of transplanted endometrial
cells
Xenograft processing
Mice bearing tumors generated following injection of pri-
mary endometrial tumor epithelial cells were euthanized
by CO2 inhalation. The generated tumors were isolated
aseptically, minced to yield 2 mm
3 pieces and incubated
with agitation at 37°C for 30 minutes in HBSS/2% FBS, 1
mM EDTA containing 1 mg/ml collagenase Type II,
0.025% DNase I and 2.5 μg/ml amphotericin B. Cells
were filtered through a 100 μm mesh filter (BD Bios-
ciences) and washed 3 × 5 minutes in HBSS/2% FBS/1
mM EDTA. Pelleted cells were resuspended in ACK lysis
buffer (Cambrex) for 1 minute at room temperature to
lyse red blood cells. The remaining cells were washed in
HBSS, resuspended in HBSS/2% FBS/1 mM EDTA and
layered over Ficoll-Paque™ PLUS (GE Healthcare Bio-
Sciences Corp., Piscataway, NJ). Non-viable cells were
eliminated from the suspension using a Dead Cell
Removal Kit (Miltenyi Biotec Inc.). H-2K
d+ mouse cells
were removed using a FITC conjugated antibody (BD
Biosciences) and MACS® LD separation columns (Milte-
nyi Biotec Inc) as per manufacturers’ recommendations.
H-2K
d- cells were suspended in 1:1 PBS/Matrigel® and
injected s.c. into the right dorsal side of NOD/SCID
mice. Tumor development was assessed bi-weekly.
CD133 isolation via magnetic beads
Isolated H-2K
d- cells were separated into CD133
+ and
CD133
- fractions using CD133 microbeads (Miltenyi
Biotec Inc.) and MACS® LD separation columns as per
manufacturers’ recommendations. To acquire a pure
CD133
- population, CD133
- cells were passed twice
through separate LD columns. Defined numbers of
CD133
+ and CD133
- cells were injected into NOD/
SCID mice as previously described.
Flow cytometry
CD133 profiling
To examine expression of CD133, single human endo-
metrial cells from primary or transplanted tumors were
isolated as outlined previously [33]. Following incuba-
tion with FcR blocking reagent (Miltenyi Biotec Inc.) to
reduce unwanted binding of antibody to Fc receptor-
expressing cells, tumor cells were resuspended in PBS/
2% FBS/1 mM EDTA and stained with 0.5 μga n t i -
CD133 (phycoerythrin (PE)-conjugated; Miltenyi Biotec
Inc.). Respective IgG isotype antibodies were included as
negative controls. Non-viable cells were excluded using
Table 1 Pathological evaluation of the human
endometrial tumor samples used
Sample ID Pathology
T1 Grade 1 Endometrioid
T2 Grade 3 Endometrioid
T3 Grade 3 Endometrioid
T4 Grade 1 Endometrioid
T5 Grade 1 Endometrioid
T6 Grade 1 Endometrioid
T7 Grade 2-3 Endometrioid
T8 Grade 3 Endometrioid
T9 Grade 1 Endometrioid
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Carlsbad, CA) as per manufacturer’s recommendations.
For primary tumors, CD31
+ and CD45
+ cells were
excluded using FITC-conjugated CD31 and CD45 anti-
bodies (Miltenyi Biotec Inc.) Similarly, for xenograft
tumors, H-2K
d+ cells were eliminated using a FITC-
conjugated H-2K
d antibody. After washing in PBS/2%
FBS/1 mM EDTA, cells were fixed by incubation in 4%
paraformaldehyde for 60 minutes and analyzed using a
LSRII (BD Biosciences) within 24 hours. Data were ana-
lyzed using FlowJo version 8.2 software.
Cell sorting
Single cell suspensions derived from endometrial xeno-
graft tumors were stained with anti-CD133 as described.
CD133
+ and CD133
- cell populations were separated
using a FACSAria flow cytometer, with post-sort analy-
sis performed to confirm population purity. Sorted cell
populations were serially diluted in 1:1 PBS:Matrigel®
and injected s.c. into female NOD/SCID mice.
Oligonucleotide array CGH (aCGH)
Array CGH was performed to determine if there were
any DNA copy number changes in cells derived from
serially transplanted endometrial tumors and from
tumors generated from CD133
+ and CD133
- injected
cells using Agilent Human 105K oligonucleotide micro-
arrays as per manufacturer’s instructions http://www.
home.agilent.com/agilent/home.jspx. Genomic coordi-
nates for this array are based on the NCBI build 36,
March 2006 freeze of the assembled human genome
(UCSC hg18), available through the UCSC Genome
Browser. This array provides an average spatial resolu-
tion of 21.7 kb.
Genomic DNA was isolated from primary tumors using
standard protocols. For array hybridizations, 5 micrograms
each of tumor and normal DNA were digested with Dpn
II for 3 hours at 37°C and purified with QIAquick PCR
purification columns. One microgram each of purified
tumor and normal DNA was labeled with Cy3-dCTP and
Cy5-dCTP, respectively, using Bioprime labeling kit (Invi-
trogen) in accordance with the manufacturer’si n s t r u c -
tions. Unincorporated nucleotides were removed using
Sephadex G-50 columns. Labeled tumor and reference
samples were precipitated with 50 micrograms of human
Cot-1 DNA and resuspended in 250 microliters of hybridi-
zation buffer provided in the Agilent oligonucleotide array
CGH kit. Prior to hybridization, probe mixtures were
denatured for 5 minutes at 95°C and incubated at 37°C for
30 minutes. Samples were then hybridized onto the oligo-
nucleotide array in the Agilent SureHyb microarray hybri-
dization chamber and hybridization was performed for 42
hours at 65°C. The arrays were disassembled and washed
as recommended by the manufacturer. Slides were dried
and scanned with an Axon 4000B microarray scanner
using GenePix Pro 4.0. Microarray images were analyzed
and data points generated using the Feature Extraction
software (version 9.1, Agilent Technologies) with linear
normalization (protocol-v4_91). Data were subsequently
imported into CGH Analytics software (version 3.4.40,
Agilent Technologies). Detection of gains and losses were
based on the z-score algorithm (threshold 2.5) and visual
inspection of the log2 ratios. Log2 ratios ≥0.4 in at least
five consecutive probes were considered a reliable copy
number alteration. Probes with log2 ratios greater than 2
were considered highly amplified.
CD133 immunofluorescence
Immunofluorescence was carried out on 6 micron sec-
tions of formalin-fixed, paraffin embedded (FFPE) biop-
sies from primary human endometrial and xenograft
tumors. Antigen retrieval was carried out using 10 mM
Citrate (pH 6.0). After blocking, sections were incubated
with CD133 antibody (K-18; Santa Cruz) or Goat Nega-
t i v eC o n t r o la t1 : 5 0d i l u t i o no v e r n i g h ta t4 ° C .D o n k e y
anti-goat Alexa Fluor 568 was used as secondary anti-
body. DAPI was used to stain nuclei.
Methylation analysis of CD133 promoter
Human endometrial cancer cell lines were treated with
either vehicle or 5-aza-2’-deoxycytidine for 72 hours.
CD133 expression was evaluated by RT-PCR and flow
cytometry.
Expression of CD133 mRNA in benign and malignant
samples
FFPE tissue specimens were obtained from the MGH
Pathology archives with IRB approval. Histological review
was performed by a pathologist on hematoxylin and
eosin stained slides to confirm pathology and designate
areas of tumor on relevant slides. Tissue was macrodis-
sected from serial 5 micron slides and total nucleic acids
were extracted using a custom fully-automated platform
based on the FormaPure System (Beckman Coulter
Genomics, Danvers, MA) and Beckman Coulter Biomek
NX
P workstation.
RT-PCR analysis
Single stranded cDNA was prepared with the Super-
script First-Strand System (Invitrogen). Mock reactions
were prepared under the same conditions but lacked
reverse transcriptase. The cDNAs were amplified by
PCR using the following primer sets: CD133-3: 5’-
AGCTTCTCTGGATTTTGCTCA-3’ (forward) and 5’-
CACAGAAAGACATCAACAGCAG-3’ (reverse);
CD133-5: 5’-CAGAAGGCATATGAATCCAAAA-3’
(forward) and 5’-CTGTCGCTGGTGCATTTCT-3’
(reverse); b-actin: 5’-CTTCCAGCCTTCCTTCCTG-3’
(forward) and 5’-TTGGCGTACAGGTCTTTGC-3’
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agarose gel elctrophoresis.
Bisulfite-treated genomic DNA sequencing
Genomic DNA was isolated from normal endometrium
and endometrial tumor using the high pure PCR tem-
plate preparation kit (Roche). Bisulfite treatment was
carried out using EZ DNA methylation kit (Zymo
Research). Mapping of methylated cytosines was carried
out by bisulfite-treated genomic DNA sequencing. The
CD133 promoter region that encompasses the CpG
island was divided into three regions defined by the
PCR primers used to amplify the bisulfite-treated DNA.
Ten individual clones were analyzed per region and tis-
sue sample. The percentage of CpG methylation within
each region was compared between benign and malig-
nant tissue. All malignant tissues analyzed (n = 3,
T7-T9) were endometrioid endometrial adenocarcinoma.
Benign endometrial tissue (n = 3) was derived from pre-
menopausal women with no evidence of malignant dis-
ease who were undergoing hysterectomy as a result of
extensive uterine fibroids.
Statistical analysis
Student’s t test was used for statistical comparisons
where appropriate. A p value of < 0.05 for the t test was
considered to be statistically significant.
Results
Assessment of CD133 expression in primary human
endometrial tumors
Other investigators have reported the presence of CD133
expressing cells in gynecologic tumors [21-23,26,33,34].
We analyzed CD133 expression in primary endometrial
tumors dissociated to single cell suspensions that were
depleted of CD31
+ endothelial cells and CD45
+ hemato-
poietic cells. The percentage of CD133
+ cells within the
total tumor cell population was determined by flow cyto-
metric analysis using a phycoerythrin (PE)-conjugated
anti-CD133 antibody. The results from analyses of three
independent primary endometrial tumors (T1-T3) are
s h o w ni nF i g u r e1 A .F i g u r e1 Bi sar e p r e s e n t a t i v ee x a m -
ple of the flow data generated in these analyses. CD133
+
cells comprised 5.7%-27.4% of the total tumor cell popu-
lation in the analyzed primary tumors, which is similar to
the range reported by Rutella and colleagues [23].
Serial transplantation of human endometrial tumor
xenografts
We have developed an in vivo experimental system in
which primary human endometrial tumors are propa-
gated and expanded through serial passaging in immu-
nocompromised NOD/SCID mice. We have used this
system in our studies of tumor initiating cells in ovarian
cancer [33] and have successfully adapted it for analysis
of similar populations in human endometrial tumors.
The system allows us to expand the limited amount of
primary endometrial tumor ti s s u es a m p l eo b t a i n e da t
the time of surgery in the absence of in vitro culturing
and thereby avoids potential artifactual influences of cul-
ture or medium conditions. To date, we have carried
out 3-4 rounds of serial transplantation with seven inde-
pendent primary human endometrial tumors of varying
grade and histological subtype. In all cases, tumor histo-
pathology has been maintained across the serial passa-
ging process (Figure 2), indicating that xenograft tumors
expanded in this in vivo system reliably model the origi-
nal primary tumor.
Differential tumor initiating capacity of CD133
+ cells
We used our serial transplantation system to determine
if CD133 identifies tumor initiating cells in human
endometrial cancer as previously reported [33]. In pilot
experiments, we utilized a magnetic bead based separa-
tion method to generate tumor-derived cell populations
enriched for CD133
+ or CD133
- cells, which were then
injected into NOD/SCID mice to assess the relative
tumorigenicity of each fraction. Following injection of
the isolated cell fractions, tumor developed in 3/3 mice
injected with 50,000 CD133
+ cells with a latency of
43 days. In contrast, only 1/3 mice injected with CD133
-
cells developed a tumor and the latency was 89 days.
Our results from the magnetic bead isolation studies
suggested that CD133
+ cells derived from human endo-
metrial tumors had enhanced tumor initiation capacity
relative to their CD133
- counterparts. To further investi-
gate this possibility, we carried out cell sorting experi-
ments to generate highly purified populations of CD133
+ and CD133
- cells and analyzed the relative tumorigeni-
city of each population as well as that of the unsorted
parent tumor cell population following injection in
NOD/SCID mice. The results of one such experiment
are shown in Table 2. In this study, injection of as few
as 500 CD133
+ cells resulted in tumor formation.
In contrast, injection of 20-200 times more bulk
unsorted or CD133
- cells were required to generate
tumors with similar latency. These findings support pre-
vious studies [23] showing that CD133
+ cells derived
from human endometrial tumors have an increased
capacity to form tumors.
Assessment of CD133 expression in serially transplanted
human endometrial tumors
We previously observed that the time to tumor forma-
tion in our serial transplantation system decreased with
each successive transplant despite fewer cells being
injected (data not shown). This was seen with all pri-
mary tumors that were successfully propagated in vivo.
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plantation enriches for a tumor initiating cell popula-
tion. To determine if the frequency of CD133
+ cells
increases over the course of serial transplantation, we
first assessed relative CD133 expression in a primary
tumor and first and third transplantation xenografts of
the same tumor by immunofluorescence. As shown in
Figure 3, CD133 expression was retained in the trans-
planted tumors. More interestingly, we observed a quali-
tative increase in the relative proportion of CD133
+ cells
Figure 1 CD133 is expressed in primary human endometrial tumors. Panel A shows the percentage of CD133
+ cells in three independent
primary human endometrial tumors (T1-T3) as determined by flow cytometry. Panel B is a representative flow cytometric analysis of the T3
primary endometrioid tumor. CD133
+ and matched IgG isotype stained populations are shown in panel B.
Figure 2 The original endometrial tumor histopathology is maintained across the serial transplantation process. Hematoxylin and eosin
stained sections from a primary human endometrial tumor (T4) and its xenograft tumors propagated over several rounds of serial
transplantation in NOD/SCID mice are shown. The histology of the parent endometrioid endometrial tumor is maintained by the tumors
generated at each serial passage. Scale bar, 50 μm.
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was not consistently evident in flow cytometric analyses
of CD133 expression in serial transplants (data not
shown).
aCGH analysis of serially transplanted tumors
The observed qualitative increase in the relative propor-
tion of CD133
+ cells in successive serial transplants may
result from genomic alterations that arise over the trans-
plantation process. To investigate this possibility, we
carried out array comparative genomic hybridization
(aCGH) analyses of xenograft tumors generated by serial
transplantation of an endometrioid endometrial tumor.
There was no evidence of gene amplification in chromo-
some region 4p15.32 which encompasses the CD133
l o c u s( F i g u r e4 ) .I n t e r e s t i n g l y ,w eo b s e r v e dn oo t h e r
major changes in copy number over serial passaging
suggesting considerable genomic stability over the trans-
plantation process.
CD133 expression is regulated by methylation
Previous reports have suggested that CD133 expression
in other tumor types [26] may be epigenetically regulated.
To determine if CD133 is regulated by methylation in
endometrial cancer, we first analyzed CD133 expression
in four different human endometrial cancer cell lines.
Cells were treated with either 5 μM 5-aza-dc or vehicle
for 72 hours. Following treatment with 5-aza-dc, CD133
mRNA levels were increased relative to the vehicle con-
trols in three of the four tested cell lines (Figure 5), sug-
gesting that CD133 expression could, at least in part, be
regulated by methylation. This was further supported by
the flow cytometric analysis of CD133 protein levels
(Table 3) following treatment with either vehicle or 5-
aza-dc in which we observed a modest increase in CD133
protein expression in three of the cell lines.
To extend these findings, we assessed whether there
was evidence of differential methylation of CpG sites in
the CD133 promoter in three sets of benign and malig-
nant tissue samples derived from women who either
had no evidence of endometrial cancer or had been
diagnosed with endometrial cancer. We focused our
analyses on three different regions of the CD133 promo-
ter which had previously been shown to be important
for the regulation of CD133 expression [26]. Figure 6A
shows the methylation pattern of three regions along
the promoter analyzed from 10 individual clones derived
from either normal benign endometrium or malignant
endometrial tumor. We detected a significant (p < 0.01)
decrease in the methylation of promoter region 1 in
malignant tumor compared to normal benign endome-
trium (Figure 6B). This approximately 3-fold drop in
CD133 promoter CpG methylation was consistently
observed in malignant endometrial tumor samples as
compared to endometrium collected from women with
no evidence of endometrial cancer. We next analyzed
the level of CD133 mRNA in these same benign and
malignant samples (Figure 6C) and detected very little if
any expression of CD133 mRNA in the benign samples
relative to the malignant samples. Finally, we analyzed
CD133 expression in benign proliferative and secretory
endometrium and in low grade malignant endometrial
tissue by immunofluorescence (Figure 7). Although we
d e t e c t e dm i n i m a lC D 1 3 3p r o t e i ne x p r e s s i o ni nt h e
benign samples, we observed more robust CD133
expression in the malignant tissue, consistent with our
methylation analyses.
Table 2 Tumorigenic capacity of CD133+ and CD133-
endometrial transplanted tumor cells in vivo
Cell dose
a, tumor formation
b and latency (days)
c
T4 1 × 10
5 1×1 0
4 1×1 0
3 5×1 0
2 1×1 0
2
CD133
+ 1/1 (54) 1/1 (56) 1/1 (61) 1/1 (61) 0/1
CD133
- 1/1 (89) 0/1 0/1 0/1 0/1
Bulk 1/1 (61) 1/1 (61) 0/1 0/1 0/1
aNumber of cells injected
bNumber of tumors formed from number of cells injected
cDays from initial injection to palpable tumor formation
Figure 3 CD133 expression increases over the course of serial transplantation. Relative CD133 expression was assessed in a human
primary endometrioid endometrial tumor (T5) and its serially passaged xenografts by immunofluorescence. The protein was predominantly
detected on the surface of endometrial cells and its expression increased with serial transplantation Scale bar, 50 μm.
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serial transplantation
Previous work utilizing serial transplantation models
demonstrated that the number of cells required to generate
tumor significantly decreased with each subsequent serial
transplantation with a concomitant decrease in the time to
onset of tumor formation [7,33]. We and others have deter-
mined that CD133 expression identifies a tumor initiating
cell population in endometrial cancer [13,23,35]. Moreover,
our present data suggest that CD133 expression is increased
over the course of serial transplantation (Figure 3). We
therefore analyzed the methylation status of the CD133
promoter in the same primary tumor sample T5 and its
first and third transplanted tumor xenografts. We observed
a reduction of methylation in region 1 in the serial trans-
plants as compared to the primary tumor sample (Figure 8).
This is the same CD133 promoter region that displayed the
most significant differences in methylation in the benign
and malignant endometrial tissue samples.
Discussion
To date, the complement of surface markers utilized for the
isolation of tumor initiating cells (also referred to as cancer
stem or cancer initiating cells) from solid tumors have var-
ied in breast (CD44
+, CD24
-/low, EpCAM
+, Lineage
- [36]),
brain (CD133
+ [18]), pancreas (CD44
+/CD24
+/EpCAM
+
[37]), colon (CD133
+ [20,38]) and prostate (CD44
+/a2b1
hi/
CD133
+ [19]) cancer. More recently, gynecological cancer
initiating cells have been isolated based on either differential
expression of a number of surface antigens (CD44
+,C D 1 1 7
+ or CD133) or differential exclusion of Hoechst dye
[13,16,33,34,39,40]. In studies to date, CD133 appears to be
one of the most consistent markers of gynecological cancer
initiating cells. While the link to tumorigenicity has been
met with some criticism [28], differential CD133 expression
has proven to be an effective tool in the isolation of sub-
populations of ovarian and endometrial cancer cells with
increased tumor forming capacity [22,23,33]. Consistent
with previous reports, we detected CD133 expressing cell
populations in tumors obtained from patients diagnosed
with endometrioid endometrial adenocarcinoma. The
CD133
+ cells had increased tumor forming capacity relative
to their CD133
- counterparts. Interestingly, we determined
that CD133 expression increased in serially transplanted
tumor xenografts when assessed by immunofluorescence
although this increase was less consistently evident in flow
Figure 4 Serial transplantation does not generate significant genomic alterations in endometrial tumors. The integrity of the genome
was assessed in the first, third and sixth serially transplanted xenograft tumors derived from endometrioid endometrial tumor sample T6 by
array comparative genomic hybridization (aCGH). As shown, the genomic profiles remain virtually unchanged across the transplant process.
Arrows indicate regions of increased and decreased DNA copy numbers detected on chromosomes 1-22 and the X chromosome.
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Page 8 of 13cytometric analyses. The differences in the results obtained
from these analyses may reflect technique-related variation
in antigen presentation/epitope exposure as described by
others [28]. The inconsistencies in the flow cytometric ana-
lyses likely result in part from variability in sample proces-
sing and antibody preparation. Our aCGH analyses
determined that the increase in CD133 expression across
the serial transplants did not result from changes in gene
copy number. We did, however, detect a relative decrease
in the level of methylation at the CD133 chromosomal
locus (data not shown). This observation led us to more
thoroughly investigate potential epigenetic regulation of
CD133 expression.
T h eC D 1 3 3g e n ew a sp r e v i o u s l yr e p o r t e dt oh a v e5
distinct promoter regions (P1-P5) that are activated in a
tissue-specific manner [41]. Promoter regions P1-P3 are
located within a CpG island and P1 and P2 are inactive
when methylated, suggesting epigenetic regulation of
these regions. We first assessed the level of CD133
mRNA in the human endometrial cancer cell lines Hec
1A, Hec 1B, AN3CA and Ishikawa and found it to be
highly variable. Treatment with a demethylating agent
resulted in an increase in the relative expression of
CD133 mRNA in three of the four cell lines, suggesting
Figure 5 CD133 expression is regulated by methylation in human endometrial cancer cell lines. CD133 expression was assessed in
triplicate by RT-PCR in the Hec1A, Hec1B, AN3CA and Ishikawa cell lines following treatment in vitro with either vehicle (0.005% DMSO, V1-V3) or
5 μM 5-aza-deoxycytidine (M1-M3). CD133 mRNA levels were increased in Hec1A, Hec1B and AN3CA cells following treatment with 5-aza-
deoxycytidine. b-actin expression was used to confirm equivalent RNA concentrations in all samples.
Table 3 Flow cytometric analysis of CD133 expression
levels after treatment with 5-aza-dC
Cell Lines Vehicle 5-aza-dC
HEC1A 0.8% 1.5%
HEC1B 0% 10%
An3Ca 0% 0%
Ishikawa 82.6% 87.3%
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Page 9 of 13Figure 6 The CD133 promoter is hypomethylated in malignant endometrial tumors. Panel A is a schematic depicting the methylation
status of the Regions 1-3 of the CD133 promoter in normal endometrium (n = 3) and malignant tumors (samples T7-T9). Ten DNA clones were
analyzed from each sample and individual CpG sites are represented by circles. The methylation of any specific CpG sites is indicated by a filled
circle. Panel B is a histogram illustrating the relative percentage of methylated CpG sites detected in the analysis shown in panel A. The
percentage of methylated CpG sites in Region 1 of the CD133 promoter was significantly decreased (p < 0.01) in malignant endometrial tumors
compared to benign endometrium. CD133 mRNA levels in a subset of the same tumor (samples T8 and T9) and normal endometrium (N1 and
N2) samples were analyzed by RT-PCR (panel C). Expression of CD133 mRNA was increased in the tumor samples relative to the benign
endometrium, consistent with the methylation patterns depicted in panel A. b-actin expression was used to confirm equivalent RNA
concentrations in all samples.
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Page 10 of 13that CD133 expression in these cell lines is regulated in
part by methylation. This hypothesis was further sup-
ported by flow cytometric analyses of the same cell lines
which determined that CD133 expression was increased
relative to vehicle treated controls following treatment
with the demethylating agent.
We next investigated the methylation status of the P1
and P2 CD133 promoter regions in primary human
endometrial tumors. Our analyses indicated that the P1
promoter region was significantly demethylated in endo-
metrial tumors compared to benign endometrium (Figure
6A). We found no obvious differences in P2 suggesting
Figure 7 CD133 protein expression is elevated in endometrial tumors. The relative expression of CD133 was evaluated in a primary
endometrial tumor and proliferative and secretory endometrium by immunofluorescence. There was robust expression of CD133 in a low grade
endometrial tumor (T4) compared to normal benign proliferative and secretory endometrium. Scale bar, 50 μm.
Figure 8 The CD133 promoter is hypomethylated over serial transplantation. The methylation status of Regions 1-3 of the CD133
promoter in human primary tumor sample T5 and its corresponding first and third serially transplanted xenografts is depicted. Ten DNA clones
were analyzed from each sample and individual CpG sites are represented by circles. The methylation of any specific CpG sites is indicated by a
filled circle.
Friel et al. Reproductive Biology and Endocrinology 2010, 8:147
http://www.rbej.com/content/8/1/147
Page 11 of 13that this promoter region is not utilized in primary human
endometrial tumors. This is in contrast to ovarian tumors,
for example, where significant differences in P2 promoter
methylation have been reported [26].
We hypothesized that the in vivo level of CD133
expression should be elevated in malignant tissue relative
to the level in benign tissue. Indeed, we detected a higher
level of CD133 protein expression in primary human
endometrial tumors compared to expression in benign
proliferative and secretory endometrium. Moreover, the
relative level of CD133 mRNA was much greater in
malignant samples when compared to the levels in
benign endometrial samples. Additionally, analysis of the
relative methylation in 3 different regions of the CD133
promoter revealed significant hypomethylation of one
region in malignant endometrial tumor tissue. Interest-
ingly, we analyzed the methylation status of a primary
tumor sample and compared it to its corresponding serial
transplants and found the level of CD133 promoter
methylation relative to that detected in the primary
human endometrial tumor appeared to be reduced over
the course of serial transplantation. As noted, the number
of cells required to generate tumor significantly decreased
with subsequent serial transplantation with a concomitant
decrease in the time to onset of tumor formation. Our
findings suggest that this may result from increased
CD133 expression due to progressive promoter hypo-
methylation. Future studies designed to determine the
transcription factors, co-activators or co-repressors that
directly or indirectly function through the methylated
CD133 promoter regions to regulate CD133 expression
may be of importance.
Conclusions
Although our results support the hypothesis that CD133
expressing cells present within the bulk human endome-
trial tumor cell population have enhanced tumor initiat-
ing capacity, it is highly unlikely that all tumor initiating
cells express CD133 or that all CD133
+ cells are tumori-
genic. Regardless, it is well accepted that patients with
advanced stage endometrial cancer have poorer prog-
nosis due to tumors that may be refractory to che-
motherapy and an increased incidence of recurrent
disease. It remains to be determined whether an increas-
ing level of CD133
+ tumor initiating cells, presumably in
part due to hypomethylation of the CD133 promoter
region contributes to the pathobiology of the advanced
stage tumor or is an indirect consequence of disease
progression.
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